NICE has reversed its preliminary rejection of Xospata (gilteritinib) and now recommends that the acute myeloid leukemia drug, made by Astellas Pharma, should be reimbursed in England for patients with the relapsed or refractory FLT3 mutation-positive form of the disease.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?